Establishing Salvia miltiorrhiza-Derived Exosome-like Nanoparticles and Elucidating Their Role in Angiogenesis

Shuya Zhang,Jiaxuan Xia,Ying Zhu,Meichen Dong,Jianxin Wang
DOI: https://doi.org/10.3390/molecules29071599
IF: 4.6
2024-04-04
Molecules
Abstract:Exosomes are multifunctional, cell-derived nanoscale membrane vesicles. Exosomes derived from certain mammalian cells have been developed as angiogenesis promoters for the treatment of myocardial ischemia–reperfusion injury, as they possess the capability to enhance endothelial cell proliferation, migration, and angiogenesis. However, the low yield of exosomes derived from mammalian cells limits their clinical applications. Therefore, we chose to extract exosome-like nanoparticles from the traditional Chinese medicine Salvia miltiorrhiza, which has been shown to promote angiogenesis. Salvia miltiorrhiza-derived exosome-like nanoparticles offer advantages, such as being economical, easily obtainable, and high-yielding, and have an ideal particle size, Zeta potential, exosome-like morphology, and stability. Salvia miltiorrhiza-derived exosome-like nanoparticles can enhance the cell viability of Human Umbilical Vein Endothelial Cells and can promote cell migration and improve the neovascularization of the cardiac tissues of myocardial ischemia–reperfusion injury, indicating their potential as angiogenesis promoters for the treatment of myocardial ischemia–reperfusion injury.
chemistry, multidisciplinary,biochemistry & molecular biology
What problem does this paper attempt to address?
The problem this paper attempts to address is the development of a novel type of Danshen (Salvia miltiorrhiza)-derived exosome-like nanoparticles (DDNs) and the exploration of their potential application in the treatment of myocardial ischemia-reperfusion (MI/R) injury. Specifically: 1. **Extraction and Purification**: Extract exosome-like nanoparticles from Danshen and purify them through ultracentrifugation and sucrose density gradient centrifugation. 2. **Characterization**: Analyze the characteristics of the extracted nanoparticles, such as particle size and Zeta potential, and confirm their exosome-like structure. 3. **Cellular Uptake**: Investigate whether these nanoparticles can be taken up by human umbilical vein endothelial cells (HUVECs). 4. **Angiogenesis Promotion Ability**: Evaluate the effect of these nanoparticles on endothelial cell proliferation and migration to verify their angiogenesis-promoting effect. 5. **In Vivo Effects**: Test the effects of these nanoparticles on cardiac function and neovascularization in a mouse model of myocardial ischemia-reperfusion injury. 6. **Safety Assessment**: Assess the biosafety of these nanoparticles in vivo through histological examination. In summary, this study aims to develop a high-yield and cost-effective plant-derived exosome-like nanoparticle for the treatment of myocardial ischemia-reperfusion injury, and to verify its potential in promoting angiogenesis and its safety.